2024年12月25日 · SLC16A1 (Solute Carrier Family 16 Member 1) is a Protein Coding gene. Diseases associated with SLC16A1 include Erythrocyte Lactate Transporter Defect and Hyperinsulinemic Hypoglycemia, Familial, 7.

Monocarboxylate transporter 1 deficiency (MCTD1) is an autosomal dominant and recessive disease on the SLC16A1/MCT1 gene on chromosome 1p13.2. It causes poor feeding and vomiting, intellectual disability, ketotic hypoglycemia, ketoacidosis, ketonuria, with episodes brought on by fasting or infection.

SLC16A1 is a prognostic marker in Kidney chromophobe, Lung adenocarcinoma, Pancreatic adenocarcinoma

2020年6月25日 · The SLC16A1 gene encodes a monocarboxylate transporter (MCT1) that mediates the movement of lactate and pyruvate across cell membranes. Import and export of these substrates by tissues such as erythrocytes, muscle, intestine, and kidney are ascribed largely to the action of a proton-coupled MCT ( Garcia et al., 1994 ).

为了确定Treg细胞在体内使用乳酸的意义，作者构建了一个组成性的Treg特异性的MCT1缺失（Slc16a1f/f Foxp3cre）小鼠，Slc16a1的缺失导致乳酸摄取的丧失。通过观察发现，MCT1缺失似乎对Treg细胞的生存和功能是可有可无的，但可能在富含乳酸的肿瘤组织中产生影响。

2024年3月30日 · This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker.

2024年3月23日 · SLC16A1 encodes a monocarboxylate transporter protein and catalyzes the proton-linked transport of monocarboxylates (e.g. L-lactate, pyruvate and ketone bodies) across the plasma membrane . In the current report, SLC16A1-mediated lactate efflux is critical for maintaining Treg cell function and inhibiting plasma cell-like dendritic cell (pDC ...

2021年9月21日 · Our study found that SLC16A1 could serve as a biomarker for the prediction of OS and PFS of urological cancers and identifying cancer subtypes with higher prognostic risk, especially in several cancers of ACC, KIRC and KICH. SLC16A1 plays a key role in promoting cancer progression and metastasis.

2024年5月20日 · To our knowledge, this is the first study to describe the role of SLC16A1 in drug resistance in CCA, and targeting SLC16A1 with combination therapy or developing specific inhibitors may become an effective strategy to improve the treatment of CCA.

Conclusion: lncRNA SLC16A1-AS1 contributes to the initiation and progression of CRC by modulating miR-515-5p to regulate MAP3K9 expression, providing potential insights for CRC treatment. Keywords: Long non-coding RNA SLC16A1-AS1, microRNA-515-5p, mitogen-activated protein kinase 9, colorectal cancer, proliferation, invasion, apoptosis Introduction